Cypher Genomics
Cypher Genomics, founded in 2011 and headquartered in San Diego, California, is a biotechnology company focused on decoding the dark proteome to uncover novel therapeutic targets.
Profile
Cypher Genomics develops AI-driven tools to uncover hidden cancer targets for novel therapies.
Cypher Genomics, founded in 2011 and headquartered in San Diego, California, is a biotechnology company focused on decoding the dark proteome to uncover novel therapeutic targets. The company’s proprietary discovery engine, RyboCypher™, combines deep sequencing of non-canonical RNAs with proteomic detection to identify disease-specific, druggable targets directly from patient tumors. These targets are integrated into CypherAtlas™, a proprietary database that serves as a foundational resource for AI-driven drug discovery.
Cypher Genomics has rapidly expanded its proprietary CypherAtlas™ to include data from approximately 1,000 patient tumor samples across 10 distinct oncology indications, identifying over 80,000 cryptic peptides, including ~15,000 cancer-specific peptides. The company’s focus on cancer-specific, membrane-bound proteins has positioned it as a leader in the field of novel target discovery. Cypher Genomics recently closed a $10 million seed financing round to accelerate its transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies. The company has also been selected to join Lilly Gateway Labs, an innovation hub operated by Eli Lilly and Company, to further advance its dark proteome discoveries into novel therapeutics.
Who buys this
- Pharmaceutical companies seeking novel therapeutic targets
- Biotechnology firms focused on oncology
- Academic research institutions studying cancer biology
- Clinical research organizations conducting oncology trials
Strengths and what to watch
Strengths
- Proprietary RyboCypher™ platform for deep sequencing and proteomic detection
- CypherAtlas™ database with over 80,000 cryptic peptides identified
- Strategic partnerships with leading institutions like Lilly Gateway Labs
Watch for
- High dependency on AI-driven discovery, which may face validation challenges
- Potential competition from larger biotech firms with similar technologies
- Regulatory hurdles in translating discoveries into approved therapies
Recent moves
Key Information
- Founded
- 2011
- Headquarters
- San Diego, California
Frequently Asked Questions
What does Cypher Genomics do?
Cypher Genomics develops AI-driven tools to uncover hidden cancer targets for novel therapies. Their proprietary RyboCypher™ platform combines deep sequencing and proteomic detection to identify disease-specific, druggable targets directly from patient tumors.
How does Cypher Genomics identify cancer targets?
Cypher Genomics uses its RyboCypher™ platform, which integrates deep sequencing of non-canonical RNAs with proteomic detection. This approach identifies cryptic peptides directly from patient tumors, enabling the discovery of novel therapeutic targets.
What is CypherAtlas™?
CypherAtlas™ is Cypher Genomics’ proprietary database that integrates identified therapeutic targets. It includes data from approximately 1,000 patient tumor samples across 10 oncology indications, identifying over 80,000 cryptic peptides, including 15,000 cancer-specific peptides.
Who are Cypher Genomics’ customers?
Cypher Genomics serves pharmaceutical companies, biotechnology firms focused on oncology, academic research institutions studying cancer biology, and clinical research organizations conducting oncology trials.
What partnerships does Cypher Genomics have?
Cypher Genomics has strategic partnerships with Lilly Gateway Labs, an innovation hub operated by Eli Lilly and Company, to advance its dark proteome discoveries into novel therapeutics.
How is Cypher Genomics funded?
Cypher Genomics recently closed a $10 million seed financing round to accelerate its transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.
Sources
- www.prnewswire.com — $10M seed financing round
- www.prnewswire.com — Selection to join Lilly Gateway Labs
- www.prnewswire.com — Market context for orphan drugs and rare diseases
- www.prnewswire.com — Collaboration with Moffitt Cancer Center